Immune Therapeutics
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income dropped to -$5,788,256 over the previous period. Total operating expenses were $1,163,493.

Profit Margin

Immune Therapeutics, Inc. (OTC:IMUN): Profit margin
2013 0 -106.06M
2014 0 -48.25M
2015 16.19K -16.31M -100721.1%
2016 3.46K -19.52M -563713.57%
2017 0 -7.31M
2018 113.5K -8.17M -7202.84%
2019 0 -4.67M
2020 0 1.10M
2021 0 3.58M
2022 0 -5.78M

IMUN Income Statement (2013 – 2022)

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue
Revenue
0000113.5K03.46K16.19K00
Cost of revenue
000047.67K00000
Gross profit
000065.82K03.46K16.19K00
Operating exp.
Research and development
14.23K152.66K126.25K336.11K144.09K399.44K444.16K977.20K7.53M22.02M
Selling and marketing
00003.23M0-401-106.58K00
Total operating expenses
1.16M738.16K887.03K2.83M4.15M5.32M9.54M10.54M35.35M95.98M
Operating income
-1.16M-738.16K-887.03K-2.83M-4.08M-5.91M-14.27M-15.80M-45.26M-95.98M
Other income (expenses), net
-2.37M4.32M2.47M-558.61K-3.35M-2.02M-6.83M-1.14M-4.67M-8.64M
Income before tax
-3.53M3.58M1.58M-3.39M-8.62M-7.93M-19.81M-16.94M-49.93M-106.06M
Income tax expense
2.25M210.91K479.93K1.27M-3.35M598.76K3.14M-364.66K-1.29M1.43M
Net income
-5.78M3.58M1.10M-4.67M-8.17M-7.31M-19.52M-16.31M-48.25M-106.06M
Earnings per share
Basic EPS
-0.160.382.4-10.44-19.03-22.81-90.09-106.45-489.84-1.85K
Diluted EPS
-0.160.382.4-10.44-19.03-22.81-90.09-106.45-489.84-1.85K
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source